Search Results 1891-1900 of 17219 for rheumatoid arthritis

  1. Phase 2b Study of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis - Mayo Clinic

    SSc classification as defined by the 2013 American College of Rheumatology/European League Against Rheumatism criteria. An enrollment cap will apply to the ...

  2. Publications - Sally B. Alcott, M.D. - Mayo Clinic

    Borgaro SR, Prigatano GP, Alcott S, Kwasnica C, Cutter N. The Patient Distress Scale questionnaire: factor structure and internal consistency. Brain Inj. 2003 ...

  3. Vinorelbine Tartrate and Cyclophosphamide in Combination with Bevacizumab or Temsirolimus in Treating Patients with Recurrent or Refractory Rhabdomyosarcoma - Mayo Clinic

    ... factor (VEGF)/vascular endothelial growth factor receptor (VEGFR-) or mammalian target of rapamycin (mTOR-) targeting agents are ineligible; Patients with ...

  4. Housecall: Start a walking group - Mayo Clinic News Network

    An opioid isn't the first choice for treating chronic conditions such as arthritis, and some side effects of opioids may be particularly concerning for older ...

  5. Radiogenomics: Exploring MRI's potential for predicting heterogeneous tumor biology - Mayo Clinic

    The model — described in the February 2021 issue of Scientific Reports — generated predictions for regional epidermal growth factor receptor (EGFR) ...

  6. Rotator Cuff Tear Arthropathy Clinical Trials - Mayo Clinic Research

    ... arthritis. . Mayo Clinic Footer. Request Appointment · Give Now · Contact Us · About Mayo Clinic · Employees · Site Map · About This Site. Legal Conditions and ...

  7. Publications - Erwin A. Kruger, M.D. - Mayo Clinic

    ... factor-mediated biological effects. Clin Cancer Res. 2002 Apr; 8 (4):1242-50. View PubMed; Price DK, Ando Y, Kruger EA, Weiss M, Figg WD. 5'-OH-thalidomide, a ...

  8. Publications - Laura E. Walker, M.D., M.B.A. - Mayo Clinic

    Anti-factor Xa Monitoring and Activated Charcoal for a Pediatric Patient With Rivaroxaban Overdose. Clin Pract Cases Emerg Med. 2018 Aug; 2 (3):247-250 Epub ...

  9. Crohn's Disease Clinical Trials

    The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin (vedolizumab intravenous [IV]), a tumor necrosis factor ...

  10. Technical Reports - Department of Quantitative Health Sciences - Mayo Clinic Research

    Population attributable risk (PAR) is a function of time because both the prevalence of a risk factor and its effect on exposed individuals may change over ...